• Citer

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

par Hadji, Peyman;Aapro, M.S.;Body, Jean-Jacques ;Bundred, N J;Brufsky, Adam;Coleman, Rosemary;Gnant, Michael;Guise, Theresa;Lipton, Allan
Référence Annals of oncology, 22, 12, page (2546-2555)
Publication Publié, 2011-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
Auteur:	Hadji, Peyman; Aapro, M.S.; Body, Jean-Jacques; Bundred, N J; Brufsky, Adam; Coleman, Rosemary; Gnant, Michael; Guise, Theresa; Lipton, Allan
Informations sur la publication:	Annals of oncology, 22, 12, page (2546-2555)
Statut de publication:	Publié, 2011-12
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	Aromatase inhibitor
	Bisphosphonate
	Bone loss
	Breast cancer
	Fracture risk
	Zoledronic acid
MeSH keywords:	Antineoplastic Agents -- adverse effects -- therapeutic use
	Aromatase Inhibitors -- adverse effects -- therapeutic use
	Bone Density Conservation Agents -- therapeutic use
	Breast Neoplasms -- drug therapy
	Diphosphonates -- therapeutic use
	Female
	Humans
	Imidazoles
	Osteoporosis, Postmenopausal -- chemically induced -- prevention & control
	Practice Guidelines as Topic
	Randomized Controlled Trials as Topic
	Risk Factors
Note générale:	Journal Article
	Research Support, Non-U.S. Gov't
	Review
	SCOPUS: re.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdr017
	info:pii/mdr017
	info:scp/80052826625
	info:pmid/21415233